Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
(NASDAQ: WVE) Delayed: 4.26 -0.09 (2.07%)
Previous Close $4.35    52 Week High $38.50 
Open $4.44    52 Week Low $8.95 
Day High $4.45    P/E N/A 
Day Low $4.20    EPS $0.00 
Volume 2,372,978       

(NASDAQ: WVE) Delayed: 4.26 -0.09 (2.07%)
Previous Close $4.35    52 Week High $38.50 
Open $4.44    52 Week Low $8.95 
Day High $4.45    P/E N/A 
Day Low $4.20    EPS $0.00 
Volume 2,372,978